|
業務類別
|
Biotechnology |
|
業務概覽
|
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals. |
| 公司地址
| 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210 |
| 電話號碼
| +1 617 461-4023 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.aktisoncology.com |
| 員工數量
| 76 |
| Mr. Matthew Roden, PhD |
President, Chief Executive Officer and Director |
-- |
05/01/2026 |
| Dr. Akos Czibere, M.D.,PhD |
Chief Medical Officer |
-- |
05/01/2026 |
| Mr. Kyle D. Kuvalanka |
Chief Financial Officer |
-- |
05/01/2026 |
| Dr. Paul L. Feldman, PhD |
Chief Scientific Officer |
-- |
05/01/2026 |
| Dr. Shulamit Ron-Bigger, PhD |
Chief Operating Officer |
-- |
05/01/2026 |
| Dr. Tyler Benedum, PhD |
Chief Technical Officer |
-- |
05/01/2026 |
|
|
| Mr. Oleg Nodelman |
Director |
05/01/2026 |
| Ms. Helen S. Kim |
Director |
05/01/2026 |
| Mr. Lloyd M. Segal |
Director |
05/01/2026 |
| Mr. Michael A. Sherman, M.B.A. |
Director |
05/01/2026 |
| Mr. Todd A. Foley, M.B.A. |
Chairman of the Board |
05/01/2026 |
| Ms. Mary T. Thistle |
Director |
05/01/2026 |
| Dr. Andrew Levin, M.D.,PhD |
Director |
05/01/2026 |
| Mr. Matthew Roden, PhD |
President, Chief Executive Officer and Director |
05/01/2026 |
| Professor Dr. Ken Herrmann |
Director |
05/01/2026 |
|
|
|
|
